841 related articles for article (PubMed ID: 17698090)
1. Management of low grade papillary bladder tumors.
Herr HW; Donat SM; Reuter VE
J Urol; 2007 Oct; 178(4 Pt 1):1201-5; discussion 1205. PubMed ID: 17698090
[TBL] [Abstract][Full Text] [Related]
2. Does the management of bladder perforation during transurethral resection of superficial bladder tumors predispose to extravesical tumor recurrence?
Skolarikos A; Chrisofos M; Ferakis N; Papatsoris A; Dellis A; Deliveliotis C
J Urol; 2005 Jun; 173(6):1908-11. PubMed ID: 15879773
[TBL] [Abstract][Full Text] [Related]
3. Pathologic features of bladder tumors after nephroureterectomy or segmental ureterectomy for upper urinary tract transitional cell carcinoma.
Raman JD; Sosa RE; Vaughan ED; Scherr DS
Urology; 2007 Feb; 69(2):251-4. PubMed ID: 17320658
[TBL] [Abstract][Full Text] [Related]
4. Conservative management of low risk superficial bladder tumors.
Pruthi RS; Baldwin N; Bhalani V; Wallen EM
J Urol; 2008 Jan; 179(1):87-90; discussion 90. PubMed ID: 17997444
[TBL] [Abstract][Full Text] [Related]
5. A surveillance schedule for G1Ta bladder cancer allowing efficient use of check cystoscopy and safe discharge at 5 years based on a 25-year prospective database.
Mariappan P; Smith G
J Urol; 2005 Apr; 173(4):1108-11. PubMed ID: 15758711
[TBL] [Abstract][Full Text] [Related]
6. Stage Ta-T1 bladder cancer: the relationship between findings at first followup cystoscopy and subsequent recurrence and progression.
Holmang S; Johansson SL
J Urol; 2002 Apr; 167(4):1634-7. PubMed ID: 11912378
[TBL] [Abstract][Full Text] [Related]
7. The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years.
Holmäng S; Hedelin H; Anderström C; Johansson SL
J Urol; 1995 Jun; 153(6):1823-6; discussion 1826-7. PubMed ID: 7752327
[TBL] [Abstract][Full Text] [Related]
8. Grade 3 bladder cancer with lamina propria invasion (pT1): characteristics of tumor and clinical course.
Takashi M; Sakata T; Murase T; Hamajima N; Miyake K
Nagoya J Med Sci; 1991 Mar; 53(1-4):1-8. PubMed ID: 1805133
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors for primary superficial transitional cell carcinoma of the bladder: a retrospective cohort study.
Yang TB; Zeng FH; Sun ZQ
Chin Med J (Engl); 2006 Nov; 119(21):1821-8. PubMed ID: 17097038
[TBL] [Abstract][Full Text] [Related]
11. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.
Gofrit ON; Shapiro A; Pode D; Sidi A; Nativ O; Leib Z; Witjes JA; van der Heijden AG; Naspro R; Colombo R
Urology; 2004 Mar; 63(3):466-71. PubMed ID: 15028439
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of an unconventional treatment modality with mistletoe lectin to prevent recurrence of superficial bladder cancer: a randomized phase II trial.
Goebell PJ; Otto T; Suhr J; Rübben H
J Urol; 2002 Jul; 168(1):72-5. PubMed ID: 12050495
[TBL] [Abstract][Full Text] [Related]
13. Lymphovascular invasion of urothelial cancer in matched transurethral bladder tumor resection and radical cystectomy specimens.
Kunju LP; You L; Zhang Y; Daignault S; Montie JE; Lee CT
J Urol; 2008 Nov; 180(5):1928-32; discussion 1932. PubMed ID: 18801529
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for local recurrence in patients with pTa/pT1 urinary bladder cancer.
Jancke G; Damm O; Rosell J; Jahnson S
Scand J Urol Nephrol; 2008; 42(5):417-21. PubMed ID: 18609266
[TBL] [Abstract][Full Text] [Related]
15. Comparison of american joint committee on cancer pathological stage T2a versus T2b urothelial carcinoma: analysis of patient outcomes in organ confined bladder cancer.
Boudreaux KJ; Clark PE; Lowrance WT; Rumohr JA; Barocas DA; Cookson MS; Smith JA; Chang SS
J Urol; 2009 Feb; 181(2):540-5; discussion 546. PubMed ID: 19084855
[TBL] [Abstract][Full Text] [Related]
16. Watchful waiting policy in recurrent Ta G1 bladder tumors.
Gofrit ON; Pode D; Lazar A; Katz R; Shapiro A
Eur Urol; 2006 Feb; 49(2):303-6; discussion 306-7. PubMed ID: 16413659
[TBL] [Abstract][Full Text] [Related]
17. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
Divrik RT; Yildirim U; Zorlu F; Ozen H
J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720
[TBL] [Abstract][Full Text] [Related]
18. Carcinoma in a bladder diverticulum: presentation and treatment outcome.
Golijanin D; Yossepowitch O; Beck SD; Sogani P; Dalbagni G
J Urol; 2003 Nov; 170(5):1761-4. PubMed ID: 14532771
[TBL] [Abstract][Full Text] [Related]
19. Ta T1 low and intermediate transitional cell carcinoma of the bladder: recurrence rates and the timing of check cystoscopies within the first year.
Guney S; Guney N; Canogullari Z; Ergenekon E
Urol Int; 2008; 80(2):124-8. PubMed ID: 18362479
[TBL] [Abstract][Full Text] [Related]
20. Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome.
Herr HW
J Urol; 2000 Jan; 163(1):60-1; discussion 61-2. PubMed ID: 10604314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
